Health Care · Biological Products, (No Diagnostic Substances)

DNA Ginkgo Bioworks Holdings, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 183021453 filings
Russell 2000

DNA at a glance

Ginkgo Bioworks Holdings, Inc. (DNA, SEC CIK 1830214) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Ginkgo Bioworks Holdings, Inc. (DNA) reported revenue of $170.2 million (down 25.1% from FY2024) and a net loss of $312.8 million. Diluted EPS was -$5.64.
  • The most recent insider open-market sale reported on Form 4 was by Kelly Jason R on October 19, 2026 of 45,682 shares at $10.14 per share.
  • In the last 90 days, DNA insiders reported 0 open-market purchases ($0) and 9 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$170.2M
−25.1% vs prior year
Insiders · 90 days
0 buys · 9 sells
Net −$1.4M
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $27.7M, down $1.7M YoY from $29.4M, driven by reduced agriculture customer services
  • Operating margin (157.5%) vs (280.1%) YoY, based on operating losses of $43.6M and $82.3M
  • Cell engineering tools costs $1.8M vs $4.6M, benefiting from lower lab automation equipment expenses
  • Cash, equivalents and marketable securities $285.4M, sufficient through at least the next 12 months
  • Nine-month operating cash flow $(117.0)M, ATM proceeds $23.0M, expenditures expected to exceed revenue through next 12 months

Risk Factors

  • No material changes to 2025 Annual Report risk factors
  • Investment risk: potential loss of all or part of invested capital
  • Business risk: adverse effects on prospects, financial condition, or operating results
  • Carried-forward risk details unavailable in provided section

AI summary of the DNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Ginkgo issued third-quarter fiscal 2026 results for the period ended September 30, 2026
  • Results press release furnished as Exhibit 99.1, containing the substantive financial details

Item EX-99.1: Item EX-99.1

  • Q3 revenue $27.7M, down 6% year over year but up from $20M in Q2, signaling sequential stabilization
  • GAAP loss from continuing operations narrowed to $41.0M from $73.4M, while Adjusted EBITDA loss improved to $22M from $53M
Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 2026 results presentation scheduled for November 5, 2026, at 4:30 p.m. ET
  • Results cover quarter ended September 30, 2026

Item 7.01: Regulation FD Disclosure

  • Q3 2026 business-performance presentation scheduled for November 5, 2026 at 4:30 p.m. ET
  • Webcast, investor Q&A, and replay available through Ginkgo’s investor-relations website
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results released for quarter ended June 30, 2026
  • Full financial figures and management commentary contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $20.2M, down 48% from $39.1M, reflecting restructuring-driven program rationalization
  • Continuing-operations net loss widened to $57.3M from $53.2M; Adjusted EBITDA loss reached $36.3M versus $25.4M

AI summaries of DNA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DNA

Don't miss the next DNA filing

  • Alerts as it files. A push when DNA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DNA, by share count.
  • Ask anything. An AI agent that reads every DNA filing and answers with sources.

DNA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Kelly Jason RSellOct 19, 2026$10.14
Canton BarrySellOct 19, 2026$10.14
Shetty Reshma P.SellOct 19, 2026$10.14
Canton BarrySellOct 19, 2026$10.14
Shetty Reshma P.SellOct 19, 2026$10.14
Coen Steven P.SellOct 19, 2026$10.14
Coen Steven P.MOct 16, 2026-
Coen Steven P.MOct 16, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$251.5M$227.0M$170.2M
Operating Income--$559.8M-$315.3M
Net Income-$892.9M-$547.0M-$312.8M
Op. Margin--246.5%-185.3%
Net Margin-355.1%-240.9%-183.8%
Balance Sheet
Total Assets-$1.4B$1.1B
Equity-$716.1M$508.6M
ROE--76.4%-61.5%
Per Share
EPS$-0.46$-10.54$-5.64
Cash Flow
Operating CF--$319.6M-$171.1M
CapEx$40.8M$62.5M$7.7M

Source: XBRL data in Ginkgo Bioworks Holdings, Inc. (DNA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

DNA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 29, 2026Analysis-
4Oct 21, 2026--
4Oct 21, 2026--
4Oct 21, 2026--
4Oct 21, 2026--
4Oct 7, 2026--
4Sep 16, 2026--
4Aug 25, 2026--
10-QAug 6, 2026Analysis
8-KAug 5, 2026Analysis-
4Jul 30, 2026--
4Jul 30, 2026--
8-KJul 30, 2026Analysis-
4Jul 30, 2026--
4Jul 20, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 12, 2026Analysis-
4May 26, 2026-
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis

Related Health Care companies

All Health Care →

DNA SEC filings: frequently asked questions

Are DNA insiders buying or selling?

In the last 90 days, Ginkgo Bioworks Holdings, Inc. (DNA) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $1.4 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

What was DNA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Ginkgo Bioworks Holdings, Inc. (DNA) reported revenue of $170.2 million (down 25.1% from FY2024) and a net loss of $312.8 million. Diluted EPS was -$5.64. The figures come from the XBRL data in the 10-K.

What did DNA report in its latest 8-K?

Ginkgo Bioworks Holdings, Inc. (DNA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Ginkgo issued third-quarter fiscal 2026 results for the period ended September 30, 2026.

What are the latest DNA SEC filings?

Ginkgo Bioworks Holdings, Inc. (DNA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 21, 2026.

What is DNA's SEC CIK number?

Ginkgo Bioworks Holdings, Inc. (DNA)'s SEC Central Index Key (CIK) is 1830214. EDGAR lists every DNA filing under that number.

Ask anything about DNA

The research agent reads DNA's filings, financials, insider trades and 13F holders, then answers with sources.